Difference between revisions of "Moxetumomab pasudotox (Lumoxiti)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
m (→Also known as) |
||
| Line 7: | Line 7: | ||
=Also known as= | =Also known as= | ||
| − | CAT-8015 | + | *'''Code name:''' CAT-8015 |
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Intravenous medications]] | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
Revision as of 02:45, 29 November 2017
Mechanism of action
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)
Preliminary data
Hairy cell leukemia
- Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012 May 20;30(15):1822-8. Epub 2012 Feb 21. PubMed
Also known as
- Code name: CAT-8015